RGEN Repligen Corporation
Healthcare$115.19+0.11%ClosedMarket Cap: $6.50B
As of 2026-05-26
Valuation
P/E (TTM)
132.83
PEG
0.46
P/B
3.08
P/S
8.50
EV/EBITDA
36.08
DCF Value
$30.67
FCF Yield
1.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
50.3%
Operating Margin
8.8%
Net Margin
6.7%
ROE
2.5%
ROA
1.8%
ROIC
2.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $194.3M | 50.7% | $18.0M | $8.3M | $— | — |
| Q4 null | $197.9M | 47.2% | $18.6M | $13.3M | $— | — |
| FY null | $738.3M | 47.1% | $59.6M | $48.9M | $— | — |
| Q3 null | $188.8M | 53.2% | $16.8M | $14.9M | $— | — |
| Q2 null | $182.4M | 50.0% | $13.9M | $14.9M | $— | — |
| Q1 null | $169.2M | 53.6% | $6.6M | $5.8M | $— | — |
| Q4 null | $167.5M | 23.2% | $-36.5M | $-33.9M | $— | — |
| FY null | $634.4M | 43.3% | $-35.1M | $-25.5M | $— | — |
| Q3 null | $154.9M | 50.0% | $-7.8M | $-654.0K | $— | — |
| Q2 null | $158.8M | 46.2% | $7.4M | $5.7M | $— | — |
| Q1 null | $153.2M | 50.1% | $3.8M | $3.3M | $— | — |
| Q4 2023 | $155.7M | 43.4% | $-887.0K | $-25.5M | $-0.46 | — |